Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06456086
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-06-07
Brief Title:
Effect of Epstein-Barr Virus on Macrophage M2M1 Migration and EphA2 Expression in Adverse Drug Reactions
Sponsor:
First Affiliated Hospital of Kunming Medical University
Organization:
First Affiliated Hospital of Kunming Medical University
Study Overview
Official Title:
Effect of Epstein-Barr Virus on Macrophage M2M1 Migration and EphA2 Expression in Adverse Drug Reactions
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the effect of EBV reactivation or EBV reactivation added with dexamethasoneDXM in patients with adverse drug reactionsCDR through evaluating the levels on monocyte macrophage M2M1 and cytokines To investigate whether expression of EBV receptors EphA2 could specifically influence on EBV activation in CDRs We performed a prospective longitudinal study on the frequencies of Monocyte Macrophage M2M1 and cytokines included IL-4IL-13TNF-αIFN-γIFN-β CXCL9 and CXCL10 after onset of MPE SJSTEN and control groups PBMCs collected from peripheral blood were cocultured with EBV or EBV with DXM We next examined whether EBV or EBV with DXM could have a strong impact on the MOs Mac M2M1 and cytokines and which cytokines could be crucial for the interaction between M2M1 and EBV by in vitro cocultures Finally EphA2 were detected to evaluate reactivation of EBV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None